Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
Blake Mandell, Brooklyn, NY (US); Martin Stogniew, Lakewood Ranch, FL (US); Jennifer Louise Schmidt, Garden City, NY (US); and Markus Seelig, Kelseyville, CA (US)
Assigned to TRANSCEND THERAPEUTICS, INC., New York, NY (US)
Filed by Transcend Therapeutics, Inc., New York, NY (US)
Filed on Jul. 31, 2024, as Appl. No. 18/790,708.
Application 18/790,708 is a continuation of application No. PCT/US2024/032615, filed on Jun. 5, 2024.
Application 18/790,708 is a continuation of application No. 18/215,547, filed on Jun. 28, 2023, granted, now 12,059,402.
Application 18/790,708 is a continuation of application No. PCT/US2023/012196, filed on Feb. 2, 2023.
Application 18/215,547 is a continuation of application No. 17/887,962, filed on Aug. 15, 2022, granted, now 11,707,446, issued on Jul. 25, 2023.
Application PCT/US2023/012196 is a continuation in part of application No. PCT/US2022/074369, filed on Aug. 1, 2022.
Application 17/887,962 is a continuation of application No. PCT/US2022/074369, filed on Aug. 1, 2022.
Claims priority of provisional application 63/649,653, filed on May 20, 2024.
Claims priority of provisional application 63/553,788, filed on Feb. 15, 2024.
Claims priority of provisional application 63/607,702, filed on Dec. 8, 2023.
Claims priority of provisional application 63/605,729, filed on Dec. 4, 2023.
Claims priority of provisional application 63/602,904, filed on Nov. 27, 2023.
Claims priority of provisional application 63/471,412, filed on Jun. 6, 2023.
Claims priority of provisional application 63/437,000, filed on Jan. 4, 2023.
Claims priority of provisional application 63/328,343, filed on Apr. 7, 2022.
Claims priority of provisional application 63/325,757, filed on Mar. 31, 2022.
Claims priority of provisional application 63/255,706, filed on Oct. 14, 2021.
Claims priority of provisional application 63/240,113, filed on Sep. 2, 2021.
Claims priority of provisional application 63/230,237, filed on Aug. 6, 2021.
Prior Publication US 2024/0390322 A1, Nov. 28, 2024
1. A method of treating a neuropsychiatric illness and/or ameliorating a symptom thereof in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or an isotopologue thereof, and/or an isotopomer thereof, and/or a solvate thereof, and/or a prodrug thereof, and/or a polymorph thereof, wherein the neuropsychiatric illness is selected from a Depressive Disorder, post-traumatic stress disorder (PTSD), acute stress disorder, an Anxiety Disorder and/or Fibromyalgia.